Verastem, Inc. (VSTM)

9,22 -0,10 (-1,02%) Alla chiusura: 04:00PM EDT

Verastem, Inc.

117 Kendrick Street
Suite 500
Needham, MA 02494
United States
781 292 4200
https://www.verastem.com

Settore/i: Healthcare
Settore: Biotechnology
Impiegati a tempo pieno: 73

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Mr. Daniel W. Paterson	President, CEO & Director	897,59k	N/D	1961
Mr. Daniel Calkins	CFO and Principal Accounting & Financial Officer	401,83k	N/D	1988
Mr. Richard H. Aldrich M.B.A.	Founder and Consultant	38,39k	N/D	1954
Dr. Robert A. Weinberg Ph.D.	Co-Founder & Chair of Scientific Advisory Board	N/D	N/D	N/D
Dr. Piyush B. Gupta Ph.D.	Co-Founder	N/D	N/D	N/D
Dr. Michelle Dipp M.D., Ph.D.	Co-Founder	N/D	N/D	1976
Mr. Robert Pintar M.B.A.	Senior Vice President of Technical Operations	N/D	N/D	N/D
Dr. Jonathan Pachter Ph.D.	Chief Scientific Officer	238,18k	N/D	1958
Mr. Nate Sanburn	Senior Vice President of Corporate Development & External Engagement	N/D	N/D	N/D
Dr. Hagop Youssoufian M.D., M.Sc., Ph.D.	Head of Medical Strategy	N/D	N/D	1957

Gli importi risalgono al giorno 31 dicembre 2023 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, an orally available small molecule RAF/MEK clamp that inhibits the ras sarcoma RAF/MEK, ERK mitogen activated pathway kinase pathway which is involved in cell proliferation, migration, transformation, and survival of tumor cells; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase for various solid tumors. The company is involved in clinical studies, including RAMP 301, a randomized global confirmatory trial to evaluate the combination of Avutometinib and Defactinib for the treatment of patients with recurrent low-grade serous ovarian cancer; RAMP 201, an adaptive two-part multicenter, parallel cohort, randomized open label trial to evaluate the efficacy and safety of Avutometinib and in combination with Defactinib; and FRAME, an investigation of Avutometinib and Defactinib in patients with KRAS mutant cancers and subsequent analyses; and RAMP 204 and 205. It has license agreements with Chugai Pharmaceutical Co., Ltd. for the development, commercialization, and manufacture of products containing Avutometinib; and Pfizer Inc. to research, develop, manufacture, and commercialize products containing Pfizer's inhibitors of FAK for therapeutic, diagnostic, and prophylactic uses in humans. In addition, it has a clinical collaboration agreement with Amgen, Inc. to evaluate the combination of Avutometinib with Amgen's KRAS-G12C inhibitor LUMAKRAS which in Phase 1/2 trial entitled RAMP 203; and a discovery and development collaboration with GenFleet Therapeutics to advance new programs targeting RAS pathway-driven cancers. Verastem, Inc. was incorporated in 2010 and is headquartered in Needham, Massachusetts.

Governance aziendale

L'ISS Governance QualityScore di Verastem, Inc. al 1 aprile 2024 è 8. I criteri di valutazione fondamentali sono revisione: 9; Consiglio di Amministrazione: 8; diritti degli azionisti: 7; retribuzione: 8.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.